CY1110322T1 - Αναστολεις της her3 δραστικοτητας - Google Patents
Αναστολεις της her3 δραστικοτηταςInfo
- Publication number
- CY1110322T1 CY1110322T1 CY20091100593T CY091100593T CY1110322T1 CY 1110322 T1 CY1110322 T1 CY 1110322T1 CY 20091100593 T CY20091100593 T CY 20091100593T CY 091100593 T CY091100593 T CY 091100593T CY 1110322 T1 CY1110322 T1 CY 1110322T1
- Authority
- CY
- Cyprus
- Prior art keywords
- inhibitions
- her3 activity
- her3
- activity
- composition
- Prior art date
Links
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 title abstract 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με μια φαρμακευτική σύνθεση η οποία περιλαμβάνει ως έναν δραστικό παράγοντα έναν αναστολέα της HER3 δραστικότητας, συγκεκριμένα ένα αντι-HER3-αντίσωμα. Περαιτέρω, η χρήση αυτής της σύνθεσης για τη διάγνωση, πρόγνωση ή αντιμετώπιση νόσων υπερβολικού πολλαπλασιασμού, συγκεκριμένα νόσων όγκου γνωστοποιείται.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01119260A EP1283053A1 (en) | 2001-08-09 | 2001-08-09 | Inhibitors of HER3 activity |
EP02794590A EP1414494B1 (en) | 2001-08-09 | 2002-08-09 | Inhibitory antibodies of her3 activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110322T1 true CY1110322T1 (el) | 2015-01-14 |
Family
ID=8178284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100593T CY1110322T1 (el) | 2001-08-09 | 2009-06-03 | Αναστολεις της her3 δραστικοτητας |
Country Status (13)
Country | Link |
---|---|
US (1) | US9011851B2 (el) |
EP (3) | EP1283053A1 (el) |
JP (1) | JP5226926B2 (el) |
CN (2) | CN102078613A (el) |
AT (1) | ATE424219T1 (el) |
AU (1) | AU2002333384B2 (el) |
CA (1) | CA2456723C (el) |
CY (1) | CY1110322T1 (el) |
DE (1) | DE60231407D1 (el) |
DK (1) | DK1414494T3 (el) |
ES (1) | ES2323772T3 (el) |
PT (1) | PT1414494E (el) |
WO (1) | WO2003013602A1 (el) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
EP1495123B1 (en) | 2002-03-26 | 2013-10-30 | Zensun (Shanghai) Science and Technology Limited | Erbb3 based methods and compositions for treating neoplasms |
US8505468B2 (en) * | 2002-11-19 | 2013-08-13 | Sharp Kabushiki Kaisha | Substrate accommodating tray |
AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
EP2097754B2 (en) | 2006-11-28 | 2018-01-24 | Daiichi Sankyo Europe GmbH | Activated her3 as a marker for predicting therapeutic efficacy |
PL2716301T3 (pl) * | 2007-02-16 | 2017-10-31 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
JP5926487B2 (ja) | 2007-04-13 | 2016-05-25 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | ErbB療法に耐性である癌を治療するための方法 |
PE20090321A1 (es) * | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
CA2693013A1 (en) * | 2007-07-13 | 2009-01-22 | Prometheus Laboratories Inc. | Drug selection for lung cancer therapy using antibody-based arrays |
EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
KR20110044905A (ko) | 2008-08-15 | 2011-05-02 | 메리맥 파마슈티컬즈, 인크. | 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템 |
US8470542B2 (en) | 2008-12-01 | 2013-06-25 | Laboratory Corporation Of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
SG172983A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
WO2010085845A1 (en) * | 2009-01-28 | 2010-08-05 | The University Of Queensland | Cancer therapy and/or diagnosis |
MA33198B1 (fr) * | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
EP2425009A4 (en) * | 2009-04-29 | 2013-01-23 | Trellis Bioscience Llc | IMMUNOREACTIVE ENHANCED ANTIBODIES WITH HEREGULINE COUPLE HER3 |
ES2647466T3 (es) | 2009-11-13 | 2017-12-21 | Daiichi Sankyo Europe Gmbh | Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3 |
PE20121616A1 (es) * | 2009-12-22 | 2012-12-05 | Roche Glycart Ag | Anticuerpos anti-her3 |
PL2544680T3 (pl) | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
BR112012025730B1 (pt) | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão |
EP2590654B1 (en) | 2010-07-09 | 2016-12-21 | Exelixis, Inc. | Combinations of kinase inhibitors for the treatment of cancer |
UA114883C2 (uk) | 2010-08-20 | 2017-08-28 | Новартіс Аг | Антитіло до рецептора епідермального фактора росту-3 (her3) |
TW201302793A (zh) * | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
DK2635604T3 (en) | 2010-11-01 | 2017-02-27 | Symphogen As | PAN-HER-ANTIBODY COMPOSITION |
JP2014508782A (ja) | 2011-03-11 | 2014-04-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ホルモン不応性乳癌の治療におけるegfrファミリー受容体の阻害剤の使用 |
KR20140023921A (ko) | 2011-03-15 | 2014-02-27 | 메리맥 파마슈티컬즈, 인크. | ErbB 경로 저해제들에 대한 저항성을 극복하는 방법 |
KR101517320B1 (ko) | 2011-04-19 | 2015-05-28 | 메리맥 파마슈티컬즈, 인크. | 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체 |
DK2707391T3 (en) | 2011-05-13 | 2018-02-05 | Gamamabs Pharma | ANTIBODIES AGAINST HER3 |
KR102101806B1 (ko) * | 2011-05-19 | 2020-04-20 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항-인간-her3 항체 및 이의 용도 |
KR20140033152A (ko) | 2011-06-20 | 2014-03-17 | 교와 핫꼬 기린 가부시키가이샤 | 항erbB3 항체 |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
EA201791393A3 (ru) | 2011-09-30 | 2018-03-30 | Ридженерон Фармасьютикалз, Инк. | Антитела к erbb3 и их применение |
EP2764364B1 (en) | 2011-10-06 | 2021-08-18 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-erbb3 antibodies |
EP2788377B1 (en) * | 2011-11-09 | 2019-01-23 | The UAB Research Foundation | Her3 antibodies and uses thereof |
AU2012340766B2 (en) | 2011-11-23 | 2018-05-10 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
JP6243345B2 (ja) | 2011-12-05 | 2017-12-06 | ノバルティス アーゲー | 上皮細胞増殖因子受容体3(her3)に対する抗体 |
CN108404129A (zh) | 2012-02-23 | 2018-08-17 | 第三共欧洲有限公司 | 用于调节放射敏感性的her3抑制剂 |
AR093778A1 (es) | 2012-11-08 | 2015-06-24 | Hoffmann La Roche | PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4 |
EP2917243B1 (en) | 2012-11-08 | 2018-03-14 | F.Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
NZ708352A (en) | 2012-11-21 | 2019-10-25 | Janssen Biotech Inc | Bispecific egfr/c-met antibodies |
US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
EP2970494B1 (en) * | 2013-03-14 | 2017-12-13 | The Board of Regents of The University of Texas System | Her3 specific monoclonal antibodies for diagnostic and therapeutic use |
CN105264382A (zh) * | 2013-04-05 | 2016-01-20 | 美国控股实验室公司 | 基于检测her3活化辅助癌症的诊断、预后和治疗的系统和方法 |
EP2821071A1 (en) | 2013-07-04 | 2015-01-07 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compounds for breast cancer treatment |
US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
EP3057608A4 (en) | 2013-10-14 | 2017-10-11 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type iii domain binding molecules |
US10519247B2 (en) * | 2013-11-01 | 2019-12-31 | Board Of Regents,The University Of Texas System | Targeting HER2 and HER3 with bispecific antibodies in cancerous cells |
EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
CA2939802C (en) | 2014-04-10 | 2022-11-01 | Daiichi Sankyo Company, Limited | Anti-her3 antibody-drug conjugate |
WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
WO2015173250A1 (en) | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Anti-her3 antibodies binding to the beta-hairpin of her3 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
PL3313441T3 (pl) | 2015-06-24 | 2024-08-19 | Janssen Biotech, Inc. | Immunomodulacja i leczenie guzów litych przeciwciałami swoiście wiążącymi cd38 |
IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
BR112018006251A2 (pt) | 2015-09-30 | 2018-10-16 | Janssen Biotech Inc | anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso |
EA201990067A1 (ru) | 2016-06-21 | 2019-07-31 | Янссен Байотек, Инк. | Цистеин-модифицированные связывающие молекулы на основе домена фибронектина iii типа |
KR20190095280A (ko) | 2016-12-12 | 2019-08-14 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트와 면역 체크 포인트 저해제의 조합 |
EP3932432A1 (en) | 2016-12-14 | 2022-01-05 | Janssen Biotech, Inc. | Cd8a-binding fibronectin type iii domains |
US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
IL268102B1 (en) | 2017-01-17 | 2024-08-01 | Daiichi Sankyo Co Ltd | Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate |
CN110636861B (zh) | 2017-03-03 | 2022-07-08 | 詹森生物科技公司 | 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法 |
TWI794230B (zh) | 2017-05-15 | 2023-03-01 | 日商第一三共股份有限公司 | 抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法 |
SG11202000997YA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Improved method for producing antibody-drug conjugate |
SG11202001514XA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Novel method for producing antibody-drug conjugate |
WO2019219891A1 (en) | 2018-05-18 | 2019-11-21 | Daiichi Sankyo Co., Ltd. | Anti-muc1 antibody-drug conjugate |
GB201913079D0 (en) * | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
WO2021076546A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Cd71 binding fibronectin type iii domains |
JP2024517610A (ja) | 2021-04-14 | 2024-04-23 | アロ・バイオセラピューティクス・カンパニー | Cd71に結合するフィブロネクチンiii型ドメイン |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
CA2037440A1 (en) | 1990-03-02 | 1991-09-03 | Gregory D. Plowman | Her3: a novel egf receptor homolog |
AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5804396A (en) * | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
BR9708343A (pt) | 1996-03-27 | 1999-08-03 | Genentech Inc | Anticorpo composição linhagem de células método para determinar a presença de proteína de erbB3 e kit |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
DE69740038D1 (el) | 1996-07-12 | 2010-12-16 | Genentech Inc | |
HUP0104211A3 (en) * | 1998-11-19 | 2003-01-28 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it |
AUPQ105799A0 (en) * | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
NZ517150A (en) | 1999-08-27 | 2005-01-28 | Genentech Inc | Dosages for treatment with anti-ErbB2 antibodies |
US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
EP1228766A1 (en) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
-
2001
- 2001-08-09 EP EP01119260A patent/EP1283053A1/en not_active Withdrawn
-
2002
- 2002-08-09 CN CN2010105512370A patent/CN102078613A/zh active Pending
- 2002-08-09 DE DE60231407T patent/DE60231407D1/de not_active Expired - Lifetime
- 2002-08-09 DK DK02794590T patent/DK1414494T3/da active
- 2002-08-09 US US10/486,113 patent/US9011851B2/en active Active
- 2002-08-09 AT AT02794590T patent/ATE424219T1/de active
- 2002-08-09 ES ES02794590T patent/ES2323772T3/es not_active Expired - Lifetime
- 2002-08-09 CA CA2456723A patent/CA2456723C/en not_active Expired - Lifetime
- 2002-08-09 WO PCT/EP2002/008938 patent/WO2003013602A1/en active Application Filing
- 2002-08-09 AU AU2002333384A patent/AU2002333384B2/en not_active Expired
- 2002-08-09 JP JP2003518606A patent/JP5226926B2/ja not_active Expired - Lifetime
- 2002-08-09 CN CN028156153A patent/CN1541109B/zh not_active Expired - Lifetime
- 2002-08-09 EP EP09002792A patent/EP2067792A2/en not_active Withdrawn
- 2002-08-09 EP EP02794590A patent/EP1414494B1/en not_active Revoked
- 2002-08-09 PT PT02794590T patent/PT1414494E/pt unknown
-
2009
- 2009-06-03 CY CY20091100593T patent/CY1110322T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK1414494T3 (da) | 2009-07-06 |
JP5226926B2 (ja) | 2013-07-03 |
EP1283053A1 (en) | 2003-02-12 |
EP1414494A1 (en) | 2004-05-06 |
EP2067792A2 (en) | 2009-06-10 |
CN102078613A (zh) | 2011-06-01 |
PT1414494E (pt) | 2009-06-12 |
EP1414494B1 (en) | 2009-03-04 |
DE60231407D1 (de) | 2009-04-16 |
CA2456723C (en) | 2016-02-09 |
US20040197332A1 (en) | 2004-10-07 |
AU2002333384B2 (en) | 2007-11-15 |
CN1541109A (zh) | 2004-10-27 |
JP2005504044A (ja) | 2005-02-10 |
ATE424219T1 (de) | 2009-03-15 |
WO2003013602A1 (en) | 2003-02-20 |
CA2456723A1 (en) | 2003-02-20 |
CN1541109B (zh) | 2013-07-10 |
ES2323772T3 (es) | 2009-07-24 |
US9011851B2 (en) | 2015-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110322T1 (el) | Αναστολεις της her3 δραστικοτητας | |
DE50310516D1 (de) | Fredericamycin-derivate | |
NO20060091L (no) | Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft | |
ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
CY1113243T1 (el) | Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4 | |
BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
TR200401029T4 (tr) | Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları | |
CY1106122T1 (el) | Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση της νοσου ευepεθιστου εντερου | |
BR0116452A (pt) | Composto, composição farmacêutica, uso de um composto | |
BRPI0513959A (pt) | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos | |
DK1307227T3 (da) | Farmaceutiske sammensætninger | |
CY1111698T1 (el) | Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης | |
DE602004024037D1 (de) | Substituierte heterozyklen | |
CY1110130T1 (el) | Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α. | |
CY1117174T1 (el) | ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ | |
CY1106026T1 (el) | Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας | |
DE502004008819D1 (de) | Medikament zur wachstumsinhibierung von tumoren | |
ATE466595T1 (de) | Verbindungen und methoden für das downregulating der effekte von tgf-beta | |
EA200870058A1 (ru) | Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран | |
ATE509958T1 (de) | Gegen cathepsin s gerichtete therapie | |
CY1105317T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων | |
CY1105142T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων | |
ATE514718T1 (de) | Peptabody für krebsbehandlung | |
ATE496899T1 (de) | Tetrahydro- und dihydrochinazolinone |